Hugel has officially launched Letybo in India and is targeting 9% market share by 2026, signaling a major push into Asia's second-largest aesthetics market. The India entry follows Hugel's US expansion and reflects a deliberate strategy to build global scale outside the mature North American and European markets.
Market
Hugel Launches Letybo in India, Targets 9% Market Share by 2026
South Korean toxin maker enters India's fast-growing aesthetics market with aggressive growth targets and direct commercial infrastructure.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Hugel targets 9% market share in India by 2026—a clear signal the company is building global scale to compete with Allergan and Galderma.
India's aesthetics market is growing 15–20% annually, driven by rising disposable income, younger demographics, and growing acceptance of cosmetic procedures. A 9% share target implies Hugel expects to capture roughly 1 in 11 toxin units sold in India within two years—an ambitious but achievable goal if the company can secure physician relationships and navigate India's complex regulatory and distribution landscape. For US practices, this matters indirectly: Hugel's international expansion funds R&D and manufacturing scale, which eventually lowers per-unit toxin costs and increases competitive pressure on pricing. The India play also signals Hugel's intent to become a truly global player, not just a regional alternative.
Source: original report ↗
Frequently asked questions
What is Letybo and who makes it?
Letybo is a botulinum toxin product launched by Hugel, a South Korean toxin manufacturer, now available in India. Hugel is positioning Letybo as a competitive alternative to established toxin brands in one of the world's fastest-growing aesthetics markets.
How fast is India's aesthetics market growing?
India's aesthetics market is growing 15–20% annually, driven by rising disposable income, younger demographics, and increasing acceptance of cosmetic procedures. This makes it one of the most attractive expansion targets for global aesthetics companies.
What market share is Hugel targeting in India?
Hugel is targeting 9% market share in India by 2026, which would represent roughly 1 in 11 toxin units sold in the country. This is an aggressive but achievable goal if Hugel can secure strong physician relationships and navigate India's regulatory environment.
Why does Hugel's India expansion matter for US med spas?
Hugel's international expansion funds R&D and manufacturing scale, which eventually lowers per-unit toxin costs and increases competitive pricing pressure in the US market. It also signals Hugel's ambition to become a truly global player, not just a regional alternative.
Is Hugel new to international markets?
No—the India launch follows Hugel's US expansion, reflecting a deliberate strategy to build global scale outside mature North American and European markets. This phased international approach positions Hugel as an increasingly serious global competitor.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.